Objective: To observe the clinical efficacy of modified Linggan Wuwei Jiangxintang combined with seretide in treating chronic persistent bronchial asthma and investigate its effects on levels of interleukin-4 (IL-4)

interleukin-10 (IL-10)

interleukin-13 (IL-13)

and interleukin-17 (IL-17). Method: One hundred and forty patients were randomly divided into control group (69 cases) and observation group (71 cases) by random number table. Patients in control group received treatment of oxygen therapy

reducing phlegm

spasmolysis and infection control

and they took salmeterol xinafoate and fluticasone propionate powder for inhalation (seretide) for every morning and night

50/250 μg/time; for severe patients

compound Methoxyphenamine capsules were added for 7 days

2 capsules/time

3 times/day. Based on the treatment in control group

patients in observation group added modified Linggan Wuwei Jiangxintang

1 dose/day. The treatment course was 12 weeks for both groups. Before and after treatment

lung function was detected; forced expiratory volume in one second account for predicted value (FEV1)

and maximal expiratory flow account for normal reference value (PEF) were recorded

score of the asthma was graded by asthma control test (ACT)

and score of phlegm wheezing was also graded. Levels of IL-4

IL-10

IL-13 and IL-17 were also detected before and after treatment. Result: The total effective rate was 95.77% in observation group

higher than 85.51% in control group (P<0.05). The total effective rate for TCM symptoms was 94.37% in observation group

higher than 79.71% in control group (P<0.01). In Ridit analysis

the controlling situation for asthma in observation group was superior to that in control group (P<0.05). After treatment

the levels of FEV1 and PEF were increased in both groups (P<0.01)

and these levels in observation group were higher than those in control group (P<0.01). The levels of IL-4

IL-13 and IL-17 in observation group were lower than those in control group

and level of IL-10 was higher than that in control group after treatment (P<0.01). Conclusion: Modified Linggan Wuwei Jiangxintang combined with seretide can control asthmatic attack

relieve clinical symptoms

ameliorate lung function

and improve clinical efficacy in treatment of chronic persistent bronchial asthma

and the mechanism of action may be associated with regulating levels of IL-4

IL-10

IL-13 and IL-17.